Targeting LAG-3 to Potentiate Anti-tumor Activity: Molecular Function and Clinical Application

Gain expert insight on targeting a new immune checkpoint, LAG-3, in solid tumors in this CME/CE/CPE-certified live meeting. Register today!


  • Welcome and Introduction
  • The Mechanism of Action of LAG-3
    • The function of LAG-3 and its interactions with T-cells
  • Anti-LAG-3 Immunotherapies and Potential Synergies With Other Therapies
    • Rational for targeting LAG-3 and potential synergistic combinations
  • Clinical Trial Evidence for the Use of Anti-LAG-3 Immunotherapies Across Solid Tumors
    • Overview of agents targeting LAG-3 and clinical evidence on efficacy in solid tumors including melanoma, NSCLC, GI cancers, and HNSCC among others
  • Identifying and Managing Adverse Events with Anti-LAG-3 Therapies
    • Adverse event profiles of anti-LAG-3 monotherapy and combination approaches
  • Audience Question and Answer Session


Date / Time
Event Details


Evan J. Lipson, MD

Associate Professor of Oncology
Melanoma and Cancer Immunology Programs
Bloomberg-Kimmel Institute for Cancer Immunotherapy
Johns Hopkins University School of Medicine
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland

Tian Zhang, MD, MHS

Associate Professor
Division of Hematology & Oncology
Department of Internal Medicine
UT Southwestern Medical Center
Harold C. Simmons Comprehensive Cancer Center
Dallas, Texas

Rodabe Amaria, MD

Assistant Professor
Department of Melanoma Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Goal Statement
The goal of this program is to improve the knowledge, confidence, competence, and performance of learners in understanding and applying the latest science and clinical trial data on current and emerging anti–LAG-3 immunotherapies across tumor types to clinical practice.

Target Audience
This program is intended for medical oncologists, nurses, pharmacists, and other healthcare professionals involved in the treatment of patients with solid tumors.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Explain the mechanism of action of LAG-3 inhibitors and the rationale for combining with other cancer treatment options
  • Describe emerging clinical trial evidence of the use of anti–LAG-3 immunotherapies across tumor types
  • Identify adverse events associated with anti–LAG-3 immunotherapies and combinations to implement supportive management strategies
  • Integrate new data into clinical practice and identify patients eligible for clinical trials


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

UAN Live Event: JA4008176-0000-22-003-L01-P

UAN Virtual: JA4008176-0000-22-004-L01-P

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.